Truqap (Capivasertib) a New Drug Approved by the FDA for Breast Cancer, Costs $24,146 for 64 tablets
Truqap is A New Drug Approved by FDA for Breast Cancer Breast cancer remains one of the most common […]
Blog
Your blog category
Alvotech (ALVO) and FDA Approval for ATV02: Investing Opportunity
ALVOTECH AVT02 APPROVAL (March 2024) NASDAQ: Alvotech (ALVO) is a biopharmaceutical company that specializes in the development and manufacturing of
Donanemab: A New Drug for Dementia
Donanemab: A Groundbreaking Dementia Drug Introduction to Donanemab Donanemab, a pioneering monoclonal antibody therapy, is being developed by Eli Lilly
Minerva (NASDAQ: NERV): New Drug For Schizophrenia Under Review In February 2024
Minerva Neurosciences’ Roluperidone Under FDA Review: A Potential Game-Changer for Schizophrenia Treatment Minerva Neurosciences Inc., a clinical-stage biopharmaceutical company,